JAZZ News and Press, Jazz Pharmaceuticals plc From 05/14/23

2023-05-14 23:25:14 ET Summary Seth Klarman’s 13F portfolio value decreased from $6.13B to $5.85B this quarter. Baupost Group increased Alphabet and Fidelity National Information Services while dropping Meta Platforms, Micron Technology, and Amazon.com. The portfolio co...

2023-05-10 20:49:06 ET Jazz Pharmaceuticals PLC (JAZZ) Q1 2023 Earnings Conference Call May 10, 2023, 16:30 ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President & COO Robert Iann...

2023-05-10 16:12:33 ET Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q1 Non-GAAP EPS of $3.95 misses by $0.27 . Revenue of $892.8M (+9.7% Y/Y) misses by $5.25M . FY23 Outlook: Revenue of $3675M-$3875M vs $3.79B consensus For further details se...

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance PR Newswire Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% ...

2023-05-08 15:00:20 ET Summary Jazz is a commercial stage pharma that generated $3.7bn in revenues in 2022. The company made a net loss of >$200m, although on an adjusted basis net income is forecast to be >$1.2bn. There are issues surrounding lead product Xywav, indicat...

2023-05-03 14:00:06 ET Summary Avadel Pharmaceuticals has received full FDA approval for Lumryz, an extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The drug's once-nightly dosing regimen give...

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference PR Newswire DUBLIN , May 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Mar...

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023 PR Newswire Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial result...

Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023 PR Newswire DUBLIN , April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wedne...

2023-04-26 10:00:43 ET For further details see: Zymeworks, Jazz in pact over cancer antibody zanidatamab